Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Malignant Melanoma

  Free Subscription

Articles published in Oncogene

Retrieve available abstracts of 82 articles:
HTML format

Single Articles

    June 2020
  1. ZHANG X, Yang L, Szeto P, Abali GK, et al
    The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.
    Oncogene. 2020 Jun 19. pii: 10.1038/s41388-020-1362.
    PubMed     Abstract available

  2. FRANGEZ Z, Fernandez-Marrero Y, Stojkov D, Seyed Jafari SM, et al
    BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth.
    Oncogene. 2020 Jun 3. pii: 10.1038/s41388-020-1339.
    PubMed     Abstract available

    April 2020
  3. ZHANG X, Huang Z, Guo Y, Xiao T, et al
    The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis.
    Oncogene. 2020 Apr 14. pii: 10.1038/s41388-020-1287.
    PubMed     Abstract available

  4. UKA R, Britschgi C, Krattli A, Matter C, et al
    Temporal activation of WNT/beta-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
    Oncogene. 2020 Apr 1. pii: 10.1038/s41388-020-1267.
    PubMed     Abstract available

    March 2020
  5. YANG X, Hu F, Liu JA, Yu S, et al
    Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.
    Oncogene. 2020 Mar 25. pii: 10.1038/s41388-020-1274.
    PubMed     Abstract available

  6. YANG W, Khoury E, Guo Q, Prabhu SA, et al
    MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression.
    Oncogene. 2020 Mar 4. pii: 10.1038/s41388-020-1240.
    PubMed     Abstract available

    January 2020
  7. LI Y, Zhou Y, Li B, Chen F, et al
    WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway.
    Oncogene. 2020 Jan 31. pii: 10.1038/s41388-020-1179.
    PubMed     Abstract available

  8. WEI L, Zhang X, Wang J, Ye Q, et al
    Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice.
    Oncogene. 2020;39:122-135.
    PubMed     Abstract available

    December 2019
  9. ZHANG M, Lin X, Zhang J, Su L, et al
    Blue light-triggered optogenetic system for treating uveal melanoma.
    Oncogene. 2019 Dec 6. pii: 10.1038/s41388-019-1119.
    PubMed     Abstract available

    October 2019
  10. MISEK SA, Appleton KM, Dexheimer TS, Lisabeth EM, et al
    Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells.
    Oncogene. 2019 Oct 28. pii: 10.1038/s41388-019-1074.
    PubMed     Abstract available

    August 2019
  11. HWANG BJ, Zhang Y, Brozowski JM, Liu Z, et al
    The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression.
    Oncogene. 2019 Aug 21. pii: 10.1038/s41388-019-0961.
    PubMed     Abstract available

    July 2019
  12. XU Z, Li L, Qian Y, Song Y, et al
    Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells.
    Oncogene. 2019;38:5860-5872.
    PubMed     Abstract available

    June 2019
  13. RATHORE M, Girard C, Ohanna M, Tichet M, et al
    Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappaB signaling pathway.
    Oncogene. 2019 Jun 28. pii: 10.1038/s41388-019-0848.
    PubMed     Abstract available

    May 2019
  14. SEOANE M, Buhs S, Iglesias P, Strauss J, et al
    Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair.
    Oncogene. 2019;38:3616-3635.
    PubMed     Abstract available

    April 2019
  15. GHOSHAL A, Rodrigues LC, Gowda CP, Elcheva IA, et al
    Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0797.
    PubMed     Abstract available

  16. GE X, Li GY, Jiang L, Jia L, et al
    Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis.
    Oncogene. 2019;38:3061-3076.
    PubMed     Abstract available

    February 2019
  17. PEROTTI V, Baldassari P, Molla A, Nicolini G, et al
    An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
    Oncogene. 2019 Feb 1. pii: 10.1038/s41388-019-0729.
    PubMed     Abstract available

  18. LUBRANO S, Comelli L, Piccirilli C, Marranci A, et al
    Development of a yeast-based system to identify new hBRAFV600E functional interactors.
    Oncogene. 2019;38:1355-1366.
    PubMed     Abstract available

    January 2019
  19. PEROTTI V, Baldassari P, Molla A, Vegetti C, et al
    Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0679.
    PubMed     Abstract available

  20. EL KHARBILI M, Agaesse G, Barbollat-Boutrand L, Pommier RM, et al
    Tspan8-beta-catenin positive feedback loop promotes melanoma invasion.
    Oncogene. 2019 Jan 24. pii: 10.1038/s41388-019-0691.
    PubMed     Abstract available

  21. MANCUSO P, Tricarico R, Bhattacharjee V, Cosentino L, et al
    Thymine DNA glycosylase as a novel target for melanoma.
    Oncogene. 2019 Jan 23. pii: 10.1038/s41388-018-0640.
    PubMed     Abstract available

  22. VITIELLO M, Evangelista M, Di Lascio N, Kusmic C, et al
    Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0681.
    PubMed     Abstract available

  23. BAGATI A, Moparthy S, Fink EE, Bianchi-Smiraglia A, et al
    KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0689.
    PubMed     Abstract available

  24. KUMAR R, Njauw CN, Reddy BY, Ji Z, et al
    Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Oncogene. 2019 Jan 16. pii: 10.1038/s41388-018-0632.
    PubMed     Abstract available

  25. STIEGLITZ D, Lamm S, Braig S, Feuerer L, et al
    BMP6-induced modulation of the tumor micro-milieu.
    Oncogene. 2019;38:609-621.
    PubMed     Abstract available

    November 2018
  26. RENZIEHAUSEN A, Wang H, Rao B, Weir L, et al
    The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0563.
    PubMed     Abstract available

  27. ARAFEH R, Di Pizio A, Elkahloun AG, Dym O, et al
    RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0578.

  28. WEI CY, Zhu MX, Lu NH, Peng R, et al
    Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.
    Oncogene. 2018 Nov 1. pii: 10.1038/s41388-018-0531.
    PubMed     Abstract available

    September 2018
  29. TURNER JA, Bemis JGT, Bagby SM, Capasso A, et al
    BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0514.
    PubMed     Abstract available

  30. LECLERC J, Garandeau D, Pandiani C, Gaudel C, et al
    Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0500.
    PubMed     Abstract available

  31. KLUG LR, Bannon AE, Javidi-Sharifi N, Town A, et al
    LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
    Oncogene. 2018 Sep 21. pii: 10.1038/s41388-018-0508.
    PubMed     Abstract available

    August 2018
  32. MORRIS SM, Mhyre AJ, Carmack SS, Myers CH, et al
    A modified gene trap approach for improved high-throughput cancer drug discovery.
    Oncogene. 2018;37:4226-4238.
    PubMed     Abstract available

  33. KLOSE R, Adam MG, Weis EM, Moll I, et al
    Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis.
    Oncogene. 2018;37:4260-4272.
    PubMed     Abstract available

    July 2018
  34. KUNZ M, Loffler-Wirth H, Dannemann M, Willscher E, et al
    RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.
    Oncogene. 2018 Jul 11. pii: 10.1038/s41388-018-0385.
    PubMed     Abstract available

  35. CASTEJON-GRINAN M, Herraiz C, Olivares C, Jimenez-Cervantes C, et al
    cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage.
    Oncogene. 2018;37:3631-3646.
    PubMed     Abstract available

    June 2018
  36. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Abstract available

  37. PAULITTI A, Andreuzzi E, Bizzotto D, Pellicani R, et al
    The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.
    Oncogene. 2018;37:3399-3414.
    PubMed     Abstract available

    May 2018
  38. CAI H, Cho EA, Li Y, Sockler J, et al
    Melanoma protective antitumor immunity activated by catalytic DNA.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0306.
    PubMed     Abstract available

  39. XIAO P, Guo Y, Zhang H, Zhang X, et al
    Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment.
    Oncogene. 2018 May 24. pii: 10.1038/s41388-018-0337.
    PubMed     Abstract available

  40. ZHU B, Tang L, Chen S, Yin C, et al
    Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
    Oncogene. 2018 May 22. pii: 10.1038/s41388-018-0314.
    PubMed     Abstract available

    April 2018
  41. ZHANG YY, Tabataba H, Liu XY, Wang JY, et al
    ACTN4 regulates the stability of RIPK1 in melanoma.
    Oncogene. 2018 Apr 30. pii: 10.1038/s41388-018-0260.
    PubMed     Abstract available

  42. REYES-URIBE P, Adrianzen-Ruesta MP, Deng Z, Echevarria-Vargas I, et al
    Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0247.
    PubMed     Abstract available

    March 2018
  43. ZUO Q, Liu J, Huang L, Qin Y, et al
    AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
    Oncogene. 2018 Mar 19. pii: 10.1038/s41388-018-0205.
    PubMed     Abstract available

  44. MISKOLCZI Z, Smith MP, Rowling EJ, Ferguson J, et al
    Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
    Oncogene. 2018 Mar 16. pii: 10.1038/s41388-018-0209.
    PubMed     Abstract available

  45. LI K, Zhang TT, Wang F, Cui B, et al
    Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression.
    Oncogene. 2018 Mar 9. pii: 10.1038/s41388-018-0172.
    PubMed     Abstract available

  46. YANG JB, Zhao ZB, Liu QZ, Hu TD, et al
    FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages.
    Oncogene. 2018;37:1192-1204.
    PubMed     Abstract available

    February 2018
  47. TUSA I, Gagliardi S, Tubita A, Pandolfi S, et al
    ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
    Oncogene. 2018 Feb 27. pii: 10.1038/s41388-018-0164.
    PubMed     Abstract available

  48. YU Y, Dai M, Lu A, Yu E, et al
    PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
    Oncogene. 2018 Feb 2. pii: 10.1038/s41388-017-0061.
    PubMed     Abstract available

    October 2017
  49. ARAIZA-OLIVERA D, Feng Y, Semenova G, Prudnikova TY, et al
    Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  50. DIETRICH P, Kuphal S, Spruss T, Hellerbrand C, et al
    Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  51. GELATO KA, Schockel L, Klingbeil O, Ruckert T, et al
    Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Abstract available

    September 2017
  52. KIM KJ, Kwon SH, Yun JH, Jeong HS, et al
    STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression.
    Oncogene. 2017;36:5445-5459.
    PubMed     Abstract available

  53. KUO TF, Chen TY, Jiang ST, Chen KW, et al
    Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.
    Oncogene. 2017;36:5484-5496.
    PubMed     Abstract available

  54. PEREGO M, Maurer M, Wang JX, Shaffer S, et al
    A slow-cycling subpopulation of melanoma cells with highly invasive properties.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  55. MAURUS K, Hufnagel A, Geiger F, Graf S, et al
    The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
    Oncogene. 2017;36:5110-5121.
    PubMed     Abstract available

    August 2017
  56. CHEN XW, Yu TJ, Zhang J, Li Y, et al
    CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.
    Oncogene. 2017;36:5045-5057.
    PubMed     Abstract available

  57. LECLERC J, Ballotti R, Bertolotto C
    Pathways from senescence to melanoma: focus on MITF sumoylation.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Abstract available

    July 2017
  58. ZHANG W, Ding Y, Zhang C, Lu Q, et al
    Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
    Oncogene. 2017;36:4277-4287.
    PubMed     Abstract available

  59. HUANG L, Wang Z, Liu C, Xu C, et al
    CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner.
    Oncogene. 2017;36:4081-4086.
    PubMed     Abstract available

    June 2017
  60. LI Y, Zhou T, Wang Y, Ning C, et al
    The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.
    Oncogene. 2017;36:3760-3771.
    PubMed     Abstract available

  61. AGAESSE G, Barbollat-Boutrand L, Sulpice E, Bhajun R, et al
    A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  62. DAMSKY WE, Bosenberg M
    Melanocytic nevi and melanoma: unraveling a complex relationship.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  63. PEREZ-ALEA M, McGrail K, Sanchez-Redondo S, Ferrer B, et al
    ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Abstract available

    May 2017
  64. GIEBELER N, Schonefuss A, Landsberg J, Tuting T, et al
    Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.
    Oncogene. 2017 May 29. doi: 10.1038/onc.2017.
    PubMed     Abstract available

    April 2017
  65. MOTZIK A, Amir E, Erlich T, Wang J, et al
    Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  66. JAIN A, Tripathi R, Turpin CP, Wang C, et al
    Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  67. SCHAEFER SM, Segalada C, Cheng PF, Bonalli M, et al
    Sox2 is dispensable for primary melanoma and metastasis formation.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  68. CESARINI V, Guida E, Todaro F, Di Agostino S, et al
    Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available

    March 2017
  69. ZHAI Z, Liu W, Kaur M, Luo Y, et al
    NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    PubMed     Abstract available

  70. YANG H, Kircher DA, Kim KH, Grossmann AH, et al
    Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  71. SONG X, Hao J, Wang J, Guo C, et al
    The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling.
    Oncogene. 2017;36:1476-1486.
    PubMed     Abstract available

    February 2017
  72. LUO S, Li Y, Ma R, Liu J, et al
    Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Abstract available

    January 2017
  73. JEONG M, Lee EW, Seong D, Seo J, et al
    USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability.
    Oncogene. 2017;36:458-470.
    PubMed     Abstract available

  74. DOUDICAN NA, Orlow SJ
    Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Oncogene. 2017;36:423-428.
    PubMed     Abstract available

  75. BROWN K, Yang P, Salvador D, Kulikauskas R, et al
    WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  76. WORRALL C, Suleymanova N, Crudden C, Trocoli Drakensjo I, et al
    Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  77. DELYON J, Servy A, Laugier F, Andre J, et al
    PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  78. KIM HS, Jung M, Kang HN, Kim H, et al
    Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  79. RIVERSO M, Montagnani V, Stecca B
    KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Abstract available

  80. BIANCHI-SMIRAGLIA A, Bagati A, Fink EE, Moparthy S, et al
    Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.
    Oncogene. 2017;36:84-96.
    PubMed     Abstract available

    November 2016
  81. WANG Y, Ou Z, Sun Y, Yeh S, et al
    Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Abstract available

    October 2016
  82. FAIAO-FLORES F, Alves-Fernandes DK, Pennacchi PC, Sandri S, et al
    Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.